Read by QxMD icon Read

Prostate brachytherapy

Michael J Zelefsky, Marisa A Kollmeier, Elan Gorshein, Xin Pei, Marina Torres, Sean McBride, Laura Happersett, Gil'ad N Cohen, Yoshiya Yamada
BACKGROUND AND PURPOSE: To evaluate the incidence and predictors of hip toxicity postradiotherapy for localized prostate cancer. METHODS AND MATERIALS: 4067 prostate cancer patients were treated with external beam radiotherapy (EBRT; n=2569; 63%) or brachytherapy with or without supplemental EBRT (n=1508; 27%). 43% (n=1738) were treated with neo-adjuvant and concurrent ADT and 57% (n=2329) with radiotherapy alone. Hip toxicity was defined as moderate or severe pain upon ambulation with or without the need for hip-revision surgery...
October 15, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Tejinder Kataria, Deepak Gupta, Shikha Goyal, Shyam Singh Bisht, Ravi Chaudhary, Kushal Narang, Susovan Banerjee, Trinanjan Basu, Ashu Abhishek, Sasikumar Sambasivam, Nisha T Vishnu
Stereotactic body radiotherapy (SBRT) is being increasingly utilized in the treatment of prostate cancer. With the advent of high precision radiosurgery systems, it is possible to obtain dose distributions akin to High Dose Rate (HDR) brachytherapy with SBRT. However, urethral toxicity has a significant impact on the quality of life in prostate cancer patients. Contouring the male urethra on a computed tomography scan is difficult in the absence of an indwelling catheter. In this pictorial essay, we have used the magnetic resonance imaging obtained for radiotherapy planning to aid in delineation of the male urethra and have attempted to define guidelines for the same...
October 17, 2016: British Journal of Radiology
Daniel Sagalovich, Michael Leapman, John Sfakianos, Simon Hall, Richard Stock, Nelson Stone
PURPOSE: We aimed to evaluate the impact of timing of androgen deprivation therapy (ADT) on survival in a cohort of patients with biochemical recurrence (BCR) after brachytherapy treatment for prostate cancer. METHODS AND MATERIALS: We retrospectively identified 2366 men receiving permanent prostate brachytherapy with or without external beam radiation therapy. Patients experiencing BCR were stratified by receipt of immediate or delayed (≥3 months) ADT and prostate-specific antigen (PSA) failure threshold of 10 ng/mL...
October 12, 2016: Brachytherapy
Eric Vigneault, Khaly Mbodji, Louis-Gabriel Racine, Eric Chevrette, Marie-Claude Lavallée, André-Guy Martin, Philippe Després, Luc Beaulieu
PURPOSE: To evaluate the long-term outcomes of image-guided high-dose-rate (HDR) brachytherapy boost to the dominant intraprostatic lesion (DIL) using multiparametric magnetic resonance imaging (MRI), including spectroscopy (MRI/magnetic resonance spectroscopy [MRS]). METHODS AND MATERIALS: Between December 2009 and March 2011, 20 patients with intermediate-risk prostate cancer underwent multiparametric MRI/MRS protocol before treatment. All patients were treated with an external beam radiotherapy dose of 40 Gy, combined with an HDR brachytherapy boost of 15 Gy...
October 12, 2016: Brachytherapy
Al V Taira, Gregory S Merrick, Robert W Galbreath, Wayne M Butler, Edward Adamovich
OBJECTIVES: To evaluate whether the use of androgen deprivation therapy (ADT) in prostate brachytherapy patients impacts overall mortality (OM) in patients with lower pretreatment serum testosterone levels compared with those with normal or high baseline serum testosterone. MATERIALS AND METHODS: From October 2001 to May 2014, 1916 patients underwent brachytherapy and had a pretreatment serum testosterone. Baseline serum testosterone values were collected prospectively before initiation of therapy...
October 12, 2016: American Journal of Clinical Oncology
Romuald Zdrojowy, Janusz Dembowski, Bartosz Małkiewicz, Krzysztof Tupikowski, Wojciech Krajewski
INTRODUCTION: Prostate cancer is the most frequent cancer among males in Europe and a leading cause of cancer deaths, with similar proportion in other developed countries. For more than twenty years, external-beam radiation therapy, alongside with radical prostatectomy, has been used as a primary radical therapeutic approach for localized prostate cancer. Yet, EBRT failures relate to 22-69% following curative radiotherapy (± androgen deprivation therapy). Additionally, a proportion of these men will have a biopsy-proven local recurrence...
2016: Central European Journal of Urology
L Steentjes, S Siesling, F J Drummond, J G van Manen, L Sharp, A Gavin
We identified patient and disease characteristics associated with (1) "current" physical side-effects of any severity; and (2) "severe" physical side-effects "ever" experienced by 3,348 (54%) prostate cancer (PCa) survivors in Ireland diagnosed 2-18 years previously. Postal questionnaires collected symptoms at diagnosis, post-biopsy complications, comorbidities, primary treatments and physical side-effects post-treatment (urinary incontinence, erectile dysfunction, libido loss, bowel problems, breast changes, hot flushes, and fatigue, "ever" and "current" at time of questionnaire completion)...
October 10, 2016: European Journal of Cancer Care
Shahram Mashouf, Habib Safigholi, Tomas Merino, Abraam Soliman, Ananth Ravi, Gerard Morton, William Y Song
PURPOSE: There is strong evidence relating postimplant dosimetry for low-dose-rate prostate seed brachytherapy to local control rates. The delineation of the prostate on CT images, however, represents a challenge due to the lack of soft-tissue contrast to identify the prostate borders. This study aims at quantifying the sensitivity of prostate V100 and D90 to contouring uncertainty as clinically relevant parameters for evaluation of target coverage in postimplant dosimetry. METHODS AND MATERIALS: CT images, postoperative plans, and contours of a cohort of patients (n = 43; low risk = 55...
October 5, 2016: Brachytherapy
Annette M Ilg, Aaron A Laviana, Mitchell Kamrava, Darlene Veruttipong, Michael Steinberg, Sang-June Park, Michael A Burke, Douglas Niedzwiecki, Patrick A Kupelian, Christopher Saigal
PURPOSE: Cost estimates through traditional hospital accounting systems are often arbitrary and ambiguous. We used time-driven activity-based costing (TDABC) to determine the true cost of low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy for prostate cancer and demonstrate opportunities for cost containment at an academic referral center. METHODS AND MATERIALS: We implemented TDABC for patients treated with I-125, preplanned LDR and computed tomography based HDR brachytherapy with two implants from initial consultation through 12-month followup...
October 3, 2016: Brachytherapy
Virginia Becerra, Mónica Ávila, Jorge Jimenez, Laura Cortes-Sanabria, Yolanda Pardo, Olatz Garin, Angels Pont, Jordi Alonso, Francesc Cots, Montse Ferrer
BACKGROUND: Our objective was to assess the efficiency of treatments in patients with localized prostate cancer, by synthesizing available evidence from European economic evaluations through systematic review. METHODS: Articles published 2000-2015 were searched in MEDLINE, EMBASE and NHS EED (Prospero protocol CRD42015022063). Two authors independently selected studies for inclusion and extracted the data. A third reviewer resolved discrepancies. We included European economic evaluations or cost comparison studies, of any modality of surgery or radiotherapy treatments, regardless the comparator/s...
October 3, 2016: BMC Health Services Research
Adam C Millar, Dean S Elterman, Larry Goldenberg, Brandon Van Asseldonk, Ashley Curtis, Keith Jarvi
INTRODUCTION: Attitudes regarding the safety of testosterone replacement therapy (TRT) in hypogonadal men with prostate cancer (PCa) have changed over the past few years with the emergence of case studies suggesting a low risk of cancer progression and a better understanding of the interaction of different levels of androgen with prostate cellular metabolism. This new view has the potential to change clinical practice. METHODS: Active members of the Canadian Urological Association were surveyed about their opinions on the safety of TRT in men with low-risk PCa, as well as their current prescribing habits...
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Liana B Guedes, Jeffrey J Tosoian, Jessica Hicks, Ashley E Ross, Tamara L Lotan
PURPOSE: Men with intermediate risk prostate cancer have widely variable outcomes, with some suggesting that active surveillance or less invasive therapies (brachytherapy or focal therapy) may be appropriate for some men with Gleason Score 3+4=7 disease. Molecular markers may help further distinguish prostate cancers with aggressive behavior. Here, we tested whether loss of the PTEN tumor suppressor in 3+4=7 tumor biopsies is associated with adverse pathology at prostatectomy. MATERIALS AND METHODS: We queried prostate needle biopsies from 2000-2014 with a maximum Gleason score of 3+4=7 followed by prostatectomy...
September 27, 2016: Journal of Urology
Michael S Rutenberg, Moshe Meister, Pradip P Amin, Arif Hussain, Michael J Naslund, Young Kwok
PURPOSE: Patients with locally recurrent prostate cancer after definitive prostate brachytherapy have few evidence-based salvage options. We evaluate the efficacy and treatment-related side-effects of salvage external-beam radiotherapy (EBRT) after definitive prostate brachytherapy (PBT). METHODS AND MATERIALS: Eleven patients previously treated with definitive PBT and with biopsy-proven local-only recurrence received salvage reirradiation with EBRT. Genitourinary (GU) function was assessed with International Prostate Symptom Scores...
September 28, 2016: Brachytherapy
Peter F Orio, Paul L Nguyen, Ivan Buzurovic, Daniel W Cail, Yu-Wei Chen
PURPOSE: The use of prostate brachytherapy has continued to decline in the United States. We examined the national practice patterns of both academic and nonacademic practices performing prostate brachytherapy by case volume per year to further characterize the decline and postulate the effect this trend might have on training the next generation of residents. METHODS AND MATERIALS: Men diagnosed with prostate cancer who had undergone radiation therapy in 2004 to 2012 were identified...
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
B R Prestidge, K Winter, M G Sanda, M Amin, W S Bice, J Michalski, G S Ibbott, J M Crook, C N Catton, H A Gay, V Donavanik, D C Beyer, S J Frank, M A Papagikos, S A Rosenthal, H J J Barthold, M Roach, H M Sandler
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
J Helou, S Torres, H B Musunuru, P Cheung, D Vesprini, H T Chung, L D'Alimonte, A Ravi, M Krahn, G Morton, D A Loblaw
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
S B Johnson, N H Lester-Coll, J R Kelly, J B Yu, S K Nath
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
J C Schuler, D T Marshall
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
A Yorozu, R Kota, Y Takagawa, S Saito, K Toya, Y Shiraishi
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
A Tetreault, J M Crook, J Hamm, T Pickles, M Keyes, M McKenzie, H H Pai, F Bachand, W J Morris
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"